Home › Funds › Chicago Capital, LLC › LGND

Chicago Capital, LLC position in LGND

LIGAND PHARMACEUTICALS INC · Health Care

Chicago Capital, LLC reported holding 551,225 shares of LGND (LIGAND PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$172.2M, representing 4.21% of its reported portfolio and ranking #5 among its reported holdings. Chicago Capital, LLC has disclosed LGND holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)551.23K sh
Reported value held$172.19M
Portfolio Weight4.21%
First reportedQ3 2023
Last changeHold
Updated2026-10-15

Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR

How Chicago Capital, LLC's LGND position evolved

Chicago Capital, LLC first disclosed a stake in LGND in Q3 2023 at 360,345 shares (US$21.6M). The position peaked in Q2 2026 at 553,435 shares, worth US$174.9M. Across 13 filings, Chicago Capital, LLC increased the stake 5 time(s), trimmed it 5 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 551,225 shares valued at US$172.2M. Notable position changes include a 36% trim in Q4 2023 (shares rose 2% over the following quarter), a 124% increase in Q2 2024 (shares rose 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 360.35K $21.59M New
Q4 2023 231.51K $16.53M Reduce
Q1 2024 229.60K $16.78M Reduce
Q2 2024 514.95K $43.39M Add
Q3 2024 545.82K $54.63M Add
Q4 2024 551.59K $59.10M Add
Q1 2025 554.52K $58.30M Add
Q2 2025 571.83K $65.01M Add
Q3 2025 568.61K $100.72M Reduce
Q4 2025 561.42K $106.15M Reduce
Q1 2026 561.67K $112.14M Hold
Q2 2026 553.43K $174.94M Reduce
Q3 2026 551.23K $172.19M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LGND and 13F data

LGND (LIGAND PHARMACEUTICALS INC) is a Health Care company. 57 other funds we track also report a position in LGND — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$205.7M), Stephens Investment Management Group LLC (US$150.3M), RICE HALL JAMES & ASSOCIATES, LLC (US$85.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LGND

All LGND fund holders →

FAQ

How long has Chicago Capital, LLC held LGND?

Chicago Capital, LLC has disclosed LGND holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Chicago Capital, LLC's current position in LGND?

As of Q3 2026, Chicago Capital, LLC holds 551.23K shares of LGND (LIGAND PHARMACEUTICALS INC), valued at $172.19M, representing 4.21% of its reported portfolio and ranking #5.

Has Chicago Capital, LLC been buying or selling LGND?

In the latest 13F filing (Q3 2026), Chicago Capital, LLC held unchanged its position in LGND. The position peaked in Q2 2026 at 553.43K shares.

Which other funds hold LGND?

Other major institutional holders of LGND include CONGRESS ASSET MANAGEMENT CO, Stephens Investment Management Group LLC, RICE HALL JAMES & ASSOCIATES, LLC, among 57 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.